Search

Your search keyword '"Stephen R. Marder"' showing total 423 results

Search Constraints

Start Over You searched for: Author "Stephen R. Marder" Remove constraint Author: "Stephen R. Marder"
423 results on '"Stephen R. Marder"'

Search Results

102. Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia

103. A Cruel Irony for Clinicians Who Treat Depression

105. Older Brains are Different: Brain–Behavior Studies and Their Clinical Utility

106. Advancing drug discovery for schizophrenia

107. Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia

108. Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial

109. Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI

110. 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY

111. The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?

112. Report From the Working Group Conference on Multisite Trial Design for Cognitive Remediation in Schizophrenia

113. Apathy in first episode psychosis patients: One year follow up

114. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Adjunctive Aripiprazole for Schizophrenia or Schizoaffective Disorder Inadequately Treated With Quetiapine or Risperidone Monotherapy

115. A Brief Cognitive Assessment Tool for Schizophrenia: Construction of a Tool for Clinicians

116. Psychosocial Treatments to Promote Functional Recovery in Schizophrenia

117. Better pharmacotherapy for schizophrenia: What does the future hold?

118. Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia

119. The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

120. Schizophrenia : Recent Advances in Diagnosis and Treatment

121. Definitions of the Term ‘Recovered’ in Schizophrenia and Other Disorders

122. Neurocognition as a Treatment Target in Schizophrenia

123. Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study

124. The Texas Medication Algorithm Project Antipsychotic Algorithm for Schizophrenia

126. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments

127. Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol

128. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial

129. Aripiprazole Effects in Patients With Acute Schizophrenia Experiencing Higher or Lower Agitation

130. Determination of ziprasidone in human plasma by liquid chromatography–electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients

131. Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms

132. Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia

133. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial

134. The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery

135. The NIMH-MATRICS Consensus Statement on Negative Symptoms

136. A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole

137. The Effects of Clozapine and Risperidone on Spatial Working Memory in Schizophrenia

138. Low-Dose Fluvoxamine as an Adjunct to Reduce Olanzapine Therapeutic Dose Requirements

139. Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus

140. Physical Health Monitoring of Patients With Schizophrenia

141. Panic disorder

142. Optimizing pharmacotherapy of schizophrenia for individuals

143. Do Clozapine and Risperidone Affect Social Competence and Problem Solving?

144. Posttraumatic stress disorder: psychopathology, medical management, and dental implications

145. Supplementing Clinic-Based Skills Training With Manual-Based Community Support Sessions: Effects on Social Adjustment of Patients With Schizophrenia

146. Alcohol abuse and dependence

147. Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients

148. The Effects of Novel Antipsychotics on Glucose and Lipid Levels

149. Bipolar I disorder

150. Sexual side effects of novel antipsychotic medications

Catalog

Books, media, physical & digital resources